25 Feb Matricelf
Asaf Toker, M.D., CEO
April 21 | 2:30pm | Gaudi 3 Ballroom
Ness Ziona, Israel
(NASDAQ: MTLF)
In-Person Presentation
Matricelf is a biotechnology company in the field of tissue engineering. The company develops a platform for autologous 3D printing of tissues and organs that significantly reduce the risk of implant rejection. Using a single biopsy from the patient we develop tissues that we can 3D print, inject or simply place where needed. In 2019, we printed, for the first time in human history, a three-dimensional human heart from human tissue. The company completed successful pre-clinical studies in a number of medical conditions and our first indication is Spinal Cord Injury. Considering the fact that SCI patients have no suggested treatments and are expected to spend their life in a wheelchair motivated us to further develop the technology and specifically SCI implant. In our pre-clinical animal studies, mice treated with our implants regained their walking ability both in acute and chronic spinal cord injury models.
